NATIONAL KIDNEY FOUNDATION CO-SPONSORED PROGRAMS

CLINICAL ASPECTS OF FIBROBLAST GROWTH FACTOR 23 IN CHRONIC KIDNEY DISEASE

Chronic Kidney Disease - Mineral Bone Disorder: Implications for Cardiac Outcomes (An Application-Based Activity)

 

Available through: Dec 16, 2017

This professional educational activity will address the common medical problem of CKD-MBD and the implications for cardiac outcomes. Content will review new data related to CKD-MBD published since the 2009 KDIGO guideline on CKD-MBD. Strategies to improve patient adherence and the implications of calcium levels in CKD will also be presented. Finally, the relationship between CKD-MBD and CVD and the opportunity to improve treatment and develop strategies to improve patient management and outcomes will be explored. A case study approach will facilitate application of learning to clinical practice.   

Approved for: 1.0 **

Faculty: Geoffrey Block, MD; Kamyar Kalantar-Zadeh, MD, MPH, PhD
Cost: Free for NKF Members and non-members

Evidence-Based Use of Growth Hormone in Chronic Kidney Disease: A Quality Improvement Initiative for Optimizing Outcomes (An Application-Based Activity)

 

Available through: Nov 16, 2017

This web-based interactive virtual patient activity focuses on the issue of growth failure as a result of growth hormone dysfunction in chronic kidney disease (CKD).  Participants have the opportunity to review an expert discussion on the treatment of growth failure in CKD, with an emphasis on the role of growth hormone therapy in improving outcomes.  Recommendations for appropriate use of growth hormone therapy are presented, along with two virtual patient case studies through which participants learn how to assess, monitor, and treat patients with growth failure in CKD.     

Approved for: 1.5 **

Faculty: Bradley A. Warady, MD; John D. Mahan, MD
Cost: Free for NKF Members and non-members

 

 

 

CKD-Related Anemia and Cardiovascular Disease: What Does the Future Hold? (A Knowledge-Based Activity)

 

Available through: Sep 21, 2017

This activity will address the common medical problem of CKD related anemia and the risk of cardiovascular events. The benefits and limitations of established anemia therapies will be discussed, as well as emerging strategies for anemia management. 

Approved for: 1.0 **

Faculty: Steven Fishbane, MD; Peter McCullough, MD
Cost: Free for NKF Members and non-members

Nephropathic Cystinosis: New Insights and Approaches to Care

 

Available through: Sep 21, 2017

This activity will address the pathogenesis and management of nephropathic cystinosis (NC). Recognition, evaluation, diagnosis, and treatment will be discussed. Evidence-based management strategies, clinical evidence for available treatment options, and possible directions of future research, will also be included.

Approved for: 1.0 **

Faculty: Craig B. Langman, MD; Sandra Amaral, MD, MHS; Frederick Kaskell, MD, PhD
Cost: Free for NKF Members and non-members

Urgent and Non-Urgent Hyperkalemia (A Knowledge-Based Activity)

 

Available through: Aug 17, 2017

This activity will address the some of the considerations that inform clinical judgments essential to the evaluation and management of hyperkalemia as encountered in the outpatient arena. Program content includes a review of the cellular mechanisms that normally ensure potassium homeostasis, how these are affected by RAAS inhibitors, hyperkalemic risk assessment based on clinical trials, and characteristics of the ideal, current and emerging oral ion exchangers.

Approved for: 1.5 **

Faculty: Ishir Bhan, MD, MPH; Linda Fried, MD, MPH, FNKF; Csaba Kovesdy, MD
Cost: Free for NKF Members and non-members

CKDinform: Early Detection and Prevention (A Knowledge-Based Activity)

 

Available through: Jul 01, 2017

This activity will address the evaluation and management of chronic kidney disease (CKD) within the primary care setting. The burden of CKD to the population, modifiable CKD risk factors, and vital screening methods and interpretation of test results will be discussed. Evidence-based treatment recommendations and management plans for CKD will be presented. Topics will also include indications for renal replacement therapy and referral and education for patients with progressive CKD.

Approved for: 1.5 **

Faculty: Kirk Campbell, MD; Alexis Chettiar, RN, MSN, ACNP-BC; Sumeska Thavarajah, MD
Cost: Free for NKF Members and non-members

MANAGEMENT STRATEGIES FOR SECONDARY HYPERPARATHYROIDISM IN CKD: VITAMIN D SUPPLEMENTATION (A KNOWLEDGE-BASED ACTIVITY)

 

Available through: Jul 12, 2017

This activity will address the clinical challenge of preventing and treating secondary hyperparathyroidism (SHPT) in patients with CKD. Content will include an update on vitamin D, and will discuss the pathophysiology and consequences of SHPT. Expert faculty will also explore current and emerging strategies for the management of SHPT in CKD.

Approved for: 1.5 **

Faculty: Myles Wolf, MD, MMSc; Glenville Jones, PhD; Ishir Bhan, MD, MPH; Michael Melamed, MD
Cost: Free for NKF Members and non-members

CKD-MBD: STATE-OF-THE-ART CONSIDERATIONS FOR OPTIMAL OUTCOMES (A KNOWLEDGE-BASED ACTIVITY)

 

Available through: Jul 12, 2017

This activity will address the most recent developments in understanding and managing chronic kidney disease-mineral and bone disorder (CKD-MBD). Expert faculty will discuss new insights regarding pathogenesis, along with best practice options for diagnosis and treatment.

Approved for: 1.5 **

Faculty: Rajnish Mehrotra, MD, MS, FNKF; Ranjani Moorthi, MD, MBBS, MPH, MS; Francesca Tentori, MD, MS
Cost: Free for NKF Members and non-members

IMPROVING GLOBAL OUTCOMES IN PATIENTS WITH HEPATITIS C INFECTION IN LATE STAGE CHRONIC KIDNEY DISEASE (A KNOWLEDGE-BASED ACTIVITY)

 

Available through: Jul 12, 2017

This activity will address the management of hepatitis C virus (HCV) in patients with advanced chronic kidney disease (CKD). Screening and treatment will be discussed. Clinical evidence for novel antivirals will also be included.

Approved for: 1.5 **

Faculty: Matthew Weir, MD; David Roth, MD; Roy Bloom, MD
Cost: Free for NKF Members and non-members

Hepatitis C Virus and Chronic Kidney Disease: Evidence-Based Management and Advances in Treatment

 

Available through: Feb 28, 2017

The goal of this activity is to address the ongoing challenge of diagnosing and managing hepatitis C virus (HCV) infection in chronic kidney disease (CKD). Content will review the mechanism of HCV infection and its associations with kidney disease. Evidence-based treatment strategies will be discussed. Clinical evidence for novel antivirals will also be examined.

Approved for: 1.0 **

Faculty: Charles E. Alpers, MD; Craig E. Gordon, MD, MS; Paul Martin, MD, FRCP, FRCPI
Cost: Free for members and non-members

The Potassium Challenge in CKD: Managing Acute & Chronic Hyperkalemia (A Knowledge-Based Program)

 

Available through: Jun 26, 2017

This CME/CE Activity focuses on the pathophysiologic consequences of hyperkalemia, the limitations of current therapeutic strategies, and the risks associated with suboptimal dosing or discontinuation of RAAS therapy as a result of persistent hyperkalemia.

Approved for: 1.5 **

Faculty: Robert D. Toto, MD; Peter McCullough, MD, MPH, FNKF; Kamyar Kalantar-Zedeh, MD, MPH, PhD
Cost: Free for members and non-members

Pathogenesis and Management of Nephrotic Syndrome in Primary Podocytopathies (A knowledge-based program)

 

Available through: Jun 26, 2017

This CME/CE Activity will address the ongoing medical problem of nephrotic syndrome, including the management of proteinuria. Content will review the pathogenesis and etiologies of nephrotic syndrome. Evaluation, management strategies, and treatment options will also be addressed.

Approved for: 1.5 **

Faculty: Laurence Beck, MD, PhD, Brad Rovin, MD, Fernando Fervenza, MD, PhD

Challenges in Lipid Management: Addressing the High-Risk Patient and the Potential for Novel Therapies (A Knowledge-based Program)

 

Available through: Feb 27, 2017

This CME/CE Activity will address clinical gaps and barriers to optimal lipid management, and how to manage high-risk patients. An overview of research on novel therapies, such as PCSK9 inhibitors, will also be discussed. This activity will include online slide presentations with 3-D animated simulation segments to actively educate and engage participants.

Approved for: 1.0 **

Faculty: Martin Quan, MD, Karol E. Watson, MD, PhD, Christie M. Ballantyne, MD
Cost: Free for members and non-members